Dompe Famaceutici S.p.A.
Via Santa Lucia, 6
8 articles with Dompe Famaceutici S.p.A.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Engitix Announces $54m Series A Financing and a Strategic Collaboration with Dompé Farmaceutici Using Exscalate’s AI Supercomputing Power to Advance its Drug Discovery Pipeline in Fibrosis and Cancer
Engitix Ltd, a biopharmaceutical company with a pioneering and proprietary human extracellular matrix drug target discovery platform announced the close of its $54m Series A financing as well as a strategic collaboration with Dompé farmaceutici S.P.A.
Dompé Announces First Patient Enrollment in Phase 2b Clinical Trial Investigating Novel Mechanism of Action in Moderate to Severe Dry Eye Disease
Following the successful launch of Oxervate, the first-in-class recombinant human nerve growth factor (rhNGF) for treatment of neurotrophic keratitis (NK), Dompé embarks on a new clinical trial program to further investigate the relevance of treatment with rhNGF in Dry Eye Disease (DED).
Over the course of 2018, the FDA approved 59 different novel drugs that range for the treatment of various cancers, chronic obstructive pulmonary disease (COPD), traveler’s diarrhea, migraine headaches and more.
8/31/2018The U.S. Food and Drug Administration has had a busy August. In addition to the number of draft guidance documents the agency issued during the month, the FDA has also been busy approving a number of new treatments for a variety of diseases.
Dompe Famaceutici S.p.A. to Acquire 100% of Anabasis, an Italian Biopharmaceutical Ophthalmology Company
Dompe Famaceutici S.p.A. Release: New Frontier in the Treatment of Type 1 Diabetes -- Italian Researchers Present Findings in the Improvement of the Efficacy of Pancreatic Islet Transplantation